Scarica l'app Stockscreener
208.53
0.58%
-1.1126
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$209.64
Aprire:
$209.26
Volume 24 ore:
415.29K
Relative Volume:
0.36
Capitalizzazione di mercato:
$30.26B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
20.10
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
-2.52%
1M Prestazione:
-7.79%
6M Prestazione:
-17.12%
1 anno Prestazione:
-14.82%
Intervallo 1D:
$207.50
$211.23
Intervallo di 1 settimana:
$198.64
$213.53
Portata 52W:
$198.64
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
208.62 | 30.41B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
457.29 | 159.99B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
152.42 | 41.18B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
40.85 | 35.52B | 29.14B | 1.07B | 1.52B | 1.1995 |
ALC
Alcon Inc
|
64.13 | 31.90B | 10.40B | 980.00M | 1.61B | 1.9749 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
QRG Capital Management Inc. Has $5.39 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Resmed boosts sleep health portfolio with Noctrix buy - BioWorld News
ResMed Stock Is Down 22% in 2026: Here’s Why Analysts Still Sees $256 Fair Value - TIKR.com
Piper Sandler Maintains ResMed(RMD.US) With Hold Rating, Cuts Target Price to $233 - Moomoo
Swedbank AB Has $265.55 Million Holdings in ResMed Inc. $RMD - MarketBeat
Harel Insurance Investments & Financial Services Ltd. Decreases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Wall Street's insights into key metrics ahead of ResMed (RMD) Q3 earnings - MSN
ResMed, Inc. Hits New 52-Week Low at USD 210.67 - Markets Mojo
Resmed enters merger agreement to acquire Noctrix Health for $340 million - MassDevice
9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This Time - Investing.com
Resmed integrating AI for sleep apnea treatment - Yahoo Finance
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
Birch Capital Management LLC Reduces Stock Holdings in ResMed Inc. $RMD - MarketBeat
Stifel Nicolaus Adjusts ResMed Price Target to $235 From $265 - Moomoo
Ord Minnett Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
[Form 3] RESMED INC Initial Statement of Beneficial Ownership - Stock Titan
ResMed (RMD) CFO Brett Sandercock reports direct holding of 83,495 shares - Stock Titan
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. (RMD) Stock Analysis: Exploring a 31.99% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed (RMD) Is Down 6.7% After Earnings Beat And CFO Transition NewsWhat's Changed - Sahm
ResMed announces CFO succession - MSN
ResMed Price Target Cut 13% to A$41.72/Share by Morgans - Moomoo
CSL, Resmed, Cochlear Lead Losses on ASX - marketscreener.com
ResMed Price Target Cut 2% to A$46.50/Share by Macquarie - Moomoo
ResMed Updates CDI Count Amid Routine Share Transfers, Issuances and Buybacks - TipRanks
ResMed: Q3 result 2026 - intelligentinvestor.com.au
ResMed Inc. 2026 Q3ResultsEarnings Call Presentation (NYSE:RMD) 2026-05-03 - Seeking Alpha
ResMed Files March 2026 Quarterly Report Detailing Capital Structure and Compliance Status - TipRanks
ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix deal - MSN
ResMed (RMD) Margin Strength At 27.5% Tests Bearish Cost And GLP 1 Narratives - Sahm
ResMed Stock Fell 8% This Week. Here’s What a Strong Earnings Beat Means for the Recovery Case - TIKR.com
Why ResMed (RMD) Narrative Is Shifting As Analysts Reassess Growth And Valuation Assumptions - Yahoo Finance
Pittenger & Anderson Inc. Acquires 5,421 Shares of ResMed Inc. $RMD - MarketBeat
PFA Pension Forsikringsaktieselskab Buys Shares of 188,393 ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stake Cut by Danske Bank A S - MarketBeat
ResMed Shifts Leadership And Adds Neurology With Noctrix Acquisition - Sahm
ResMed: Stock splutters, but machine is still breathing well - marketscreener.com
Should you continue to hold Resmed stock in your portfolio? - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Immunome (IMNM) and Resmed (RMD) - The Globe and Mail
ResMed Q3 Earnings Call Highlights - Yahoo Finance
Pictet Asset Management Holding SA Sells 42,929 Shares of ResMed Inc. $RMD - MarketBeat
ResMed stock hits 52-week low at $205.86 amid market challenges - Investing.com Nigeria
Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Resmed (RMD) - The Globe and Mail
ResMed Earnings Call Highlights Margin Strength, Growth - TipRanks
ResMed Inc (RMD) Stock Down 4.1% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed on Track for Lowest Close Since July 2024 -- Data Talk - Moomoo
Research Alert: CFRA Lowers Rating On Shares Of Resmed Inc. To Sell From Hold - Moomoo
Royal Bank Of Canada Forecasts Strong Price Appreciation for ResMed (NYSE:RMD) Stock - MarketBeat
ResMed Q3 2026 earnings preview - MSN
ResMed (NYSE:RMD) Shares Down 6% on Analyst Downgrade - MarketBeat
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
12.51%
2.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):